/
Dermatology
Hidradenitis Suppurativa
29
Pipeline Programs↗
68
Active Trials↗
37
Companies Involved↗
Hidradenitis Suppurativa is an emerging landscape with 29 programs across 37 companies. The most active players are AbbVie, Novartis, MoonLake Immunotherapeutics AG. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical10
Phase 14
Phase 28
Phase 37
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
20 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 97% of 29 pipeline programs.
Analysis
Trial Status
165
clinical trials
Completed74 · 45%
Recruiting34 · 21%
Active, not recruiting21 · 13%
Not yet recruiting12 · 7%
Terminated10 · 6%
Withdrawn9 · 5%
Other5 · 3%
Clinical Trials
Trial Activity
165 trials
An Open-Label Single Center Study Evaluating the Safety and Efficacy of Roflumilast Foam 0.3% in Adolescent and Adult Subjects With Hidradenitis Suppurativa
Recruiting·—·Phase 2·NCT07689188·10 enrolled
Global Healthcare Study on Hidradenitis Suppurativa
Recruiting·—·N/A·NCT07659769·9,600 enrolled
Page 1 of 11
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)